03.26.2019 Issue 444

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Highlights from NPC, Discern Health Webinar

Saturday, March 23

A recent National Pharmaceutical Council blog post offers highlights from a Feb. 28 webinar it hosted in collaboration with Discern Health.

Questions Loom on Post-Gottlieb FDA

Article: Germany as Model for Single-Payer System

Analysis: ICER Framework in Medicaid Could Threaten 820K Prescriptions

Boston Health Economics Offers Instant Health Data Platform

Article: Taking on Low-Value Care is Key Issue


Senior Research Analyst (HEOR)

Scientific Writer

Medical Statistician

Health Economics & Real-World Evidence (HE-RWE) Scientist

Industry Spotlight


Conferences Webinars
ISPOR Warsaw 2019
    March 27-28, Warsaw, Poland

Expanded Access Programs 2019
    March 27-28, Philadelphia, Pennsylvania

META Tool Facilitation Training Day
    April 2, London, U.K.

The HealthTech Summit USA 2019
    April 4, Philadelphia, Pennsylvania

The Use of MCDA for HTA Agencies – Options, Limitations, and the Way Forward
    April 3

MCDA - How to Guide Through the Application of Different Methods for Assessment and Prioritization of Rare Disease Health Technologies
    April 4

Big Data, RWD and RWE: What’s the Difference and How is it Changing the Research Landscape?
    April 15


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
             Truven    
              Evidera    HealthCore    University of FL
Xcenda    OM1    Parexel    Jefferson     Dymaxium
Precision Xtract    Pharmerit    eMax Health    Sciformix
Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn